Saretpa Therapeutics Up 5%, Roth Capital Initiates CoverageChris Middlebrooks (Author) Published Date : Jun 17, 2014 09:49 IST
Shares of Sarepta Therapeutics (SRPT) climbed more than 5.5% after Roth Capital started coverage with a Buy rating. Roth placed a $52 price target on the stock. In afternoon trade, SRPT was up 5.62% to $32.89.
Saretpa Therapeutics Up 5%, Roth Capital Initiates Coverage